Open AccessRecomendaciones sobre el uso de palivizumab. Actualización 2015
Author(s) -
Comité de Estudios Fetoneonatales,
Fernández Jonusas S,
Albas Maubett D,
Daniela Satragno,
Adriana Cattaino,
Martin Alonso M,
Claudia Grau Rubio,
Romiieto,
Comité de Cardiología,
Comité de Neumonología,
Comité de Infectología,
Subcomisión de Epidemiología,
Subcomisión de Investigación,
Grupo de Trabajo Seguimiento de Alto Riesgo Cefen,
Expertos
Publication year - 2016
Publication title -
archivos argentinos de pediatría
Language(s) - Spanish
Resource type - Journals
SCImago Journal Rank - 0.236
H-Index - 19
eISSN - 1668-3501
pISSN - 0325-0075
DOI - 10.5546/aap.2016.84
Subject(s) - palivizumab , medicine , bronchopulmonary dysplasia , pediatrics , respiratory system , biology , gestational age , pregnancy , genetics
This recommendation updates the Argentinean Pediatrics' Neonatal Committee (CEFEN) ones published in 2007. The respiratory syncytial virus is the most frequent agent for lower respiratory infection. Tiny premature, bronchopulmonary dysplasia and significant hemodynamic congenital heart disease babies are the most vulnerable populations. Palivizumab is a humanized monoclonal antibody against respiratory syncytial virus used in the cold season. These recommendations are based on the scientific review of the literature published up to date. We reinforce the importance of general prevention measures like hand hygiene and family education among others. During the predominant season of respiratory syncytial virus in our country (April to September) a monthly dose of intramuscular 15 mg/kg of palivizumab is recommended. The safety and effectiveness has been proved as well as a reduction in the hospitalizations rates. In addition, epidemiological data of previous years are provided here.